Want to join the conversation?
$MYL announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, which is the generic version of Janssen's Ortho Tri-Cyclen Lo Tablets. $MYL received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for prevention of pregnancy.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?